Table 2

Associations between ln-transformed biomarkers of exposure to cadmium and selected markers of kidney function in multiple regression models including age, sex, weight, smoking (never/ever) and pack-years

Dependent variableK-CdB-Cd24 h U-CdON U-Cd
µg/gµg/24hµg/Lµg/hµg/L
β, SE (p value)β, SE (p value)β, SE (p value)β, SE (p value)β, SE (p value)β, SE (p value)
GFR (mL/min/1.73 m2)−0.001, 0.002 (0.52)−0.006, 0.03 (0.86)
Model 1 with U-Cd−0.044, 0.084 (0.60)−0.031, 0.11 (0.79)0.22, 1.7 (0.90)0.023, 0.047 (0.63)
Model 2 with U-Cd−0.024, 0.086 (0.78)0.047, 0.13 (0.72)0.20, 1.7 (0.91)0.047, 0.059 (0.42)
Model 3 with U-Cd−0.045, 0.085 (0.60)−0.040, 0.13 (0.76)0.18, 1.7 (0.92)0.038, 0.056 (0.49)
S-cystatin C (mg/L)−0.003, 0.003 (0.32)−0.08, 0.06 (0.19)
Model 1 with U-Cd0.18, 0.16 (0.28)0.29, 0.23 (0.21)0.15, 0.09 (0.11)
Model 2 with U-Cd0.18, 0.17 (0.30)0.37, 0.28 (0.19)0.11, 0.12 (0.35)
Model 3 with U-Cd0.17, 0.16 (0.30)0.21, 0.26 (0.41)0.13, 0.11 (0.24)
24 h U-Alb (mg/h)−0.007, 0.007 (0.34)−0.06, 0.013 (0.65)
Model 1 with U-Cd0.24, 0.33 (0.48)−0.11, 0.84 (0.41)
Model 2 with U-Cd0.24, 0.35 (0.48)−0.18, 0.52 (0.73)
Model 3 with U-Cd0.27, 0.34 (0.44)0.02, 0.51 (0.96)
ON U-Alb (mg/h)−0.007, 0.006 (0.31)0.18, 0.13 (0.16)
Model 1 with U-Cd13, 5.6 (0.054)0.06, 0.19 (0.73)
Model 2 with U-Cd13, 6.7 (0.06)0.07, 0.23 (0.76)
Model 3 with U-Cd13, 6.7 (0.06)0.16, 0.22 (0.46)
24 h U-A1M (mg/h)0.007, 0.004 (0.09)0.13, 0.07 (0.09)
Model 1 with U-Cd0.45, 0.24 (0.06)−0.32, 0.32 (0.33)
Model 2 with U-Cd0.70, 0.22 (0.002)0.28, 0.35 (0.41)
Model 3 with U-Cd0.64, 0.18 (<0.001)0.59, 0.29 (0.045)
ON U-A1M (mg/h)
Model 1 with U-Cd0.009, 0.004 (0.040)0.20, 0.08 (0.02)
Model 2 with U-Cd22, 6.6 (0.002)−0.51, 0.18 (0.008)
Model 3 with U-Cd21, 4.5 (<0.001)0.33, 0.17 (0.06)
24 h U-KIM (ng/h)−0.002, 0.008 (0.78)−0.09, 0.14 (0.56)17, 4.0 (<0.001)0.32, 0.15 (0.027)
Model 1 with U-Cd0.42, 0.36 (0.25)0.86, 0.49 (0.08)
Model 2 with U-Cd0.23, 0.36 (0.52)0.33, 0.55 (0.56)
Model 3 with U-Cd0.38, 0.36 (0.30)0.74, 0.55 (0.19)
ON U-KIM (ng/h)
Model 1 with U-Cd−0.012, 0.008 (0.15)0.014, 0.17 (0.40)
Model 2 with U-Cd14, 8.6 (0.10)0.01, 24 (0.96)
Model 3 with U-Cd14, 8.7 (0.10)−0.01, 0.30 (0.97)
24 h U-RBP (ng/h)−0.002, 0.008 (0.85)−0.034, 0.15 (0.82)17, 4.0 (<0.001)0.32, 0.14 (0.03)
Model 1 with U-Cd0.005, 0.37 (0.99)−0.40, 0.50 (0.42)
Model 2 with U-Cd−0.03, 0.38 (0.94)−0.65, 0.57 (0.26)
Model 3 with U-Cd0.04, 0.37 (0.90)−0.27, 0.56 (0.64)
ON U-RBP (ng/h)−0.006, 0.008 (0.47)0.32, 0.16 (0.04)
Model 1 with U-Cd17, 8.5 (0.05)−0.28, 0.24 (0.25)
Model 2 with U-Cd13, 8.4 (0.12)−0.20, 0.24 (0.40)
Model 3 with U-Cd15, 8.2 (0.08)0.11, 0.27 (0.69)
  • p-Values <0.10 are shown in bold.

  • Additionally, model 2 based on urinary cadmium (U-Cd) included creatinine concentration and model 3 urinary flow rate. For each model, the β coefficient, its SE and p value is given.

  • A1M, α-1-microglobulin; B, blood; Alb, albumin; Cd, cadmium; GFR, glomerular filtration rate; K, kidney; KIM, kidney injury molecule; ON, overnight sample; RBP, retinol-binding protein; U, urine.